Develops long-acting biologic therapies for retinal diseases like wet age-related macular degeneration.
Develops long-acting biologic therapies for retinal diseases like wet age-related macular degeneration.
Has no products on the market and no sales; operating costs are paid from money raised from investors, with cash use driven by late-stage trials. Future income depends on trial results and regulatory approval for tarcocimab and related antibody drugs.
Moat: none (IP / patents). Aims for less-frequent dosing than approved anti-VEGF drugs, but has faced repeated clinical setbacks.
Headquarters: Palo Alto, California, US · Founded: 2009 · Employees: 124
Size Kodiak Sciences (KOD) is a United States Health Care company (Biotechnology) with a market value of $6.40B, the 1011th largest of 3,085 United States companies the cockpit tracks. Shares closed at $97.81 on 18 Nov 2026.
Performance Over six months the shares gained 170.0%, against -1.4% for the median peer and -2.2% for the United States market (cap-weighted) — highest of 21 in its peer set.
Valuation It trades at 500.31× book value against a peer median of 8.92× (most expensive of 21).
Price implies The share price implies a return on equity of about 6,084.6%; Kodiak Sciences delivers -1,360.9%, so the price asks more than the business earns today.
Short interest Short interest is 12.9% of the free float (30 Oct 2026).
Next results Next results expected around 1 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Revenue growth | — | — | — | — | — |
| Gross profit | -$23.9M | -$26.3M | -$26.7M | -$25.9M | -$11.0M |
| EBITDA | -$227M | -$206M | -$160M | -$251M | -$330M |
| Net income | -$247M | -$230M | -$176M | -$260M | -$334M |
| Free cash flow | -$173M | -$137M | -$118M | -$196M | -$254M |
| Capital expenditure | $3.32M | $506,000 | $400,000 | $41.4M | $47.4M |
| Total debt | $147M | $159M | $170M | $182M | $188M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | ROE | Price / book | Implied ROE |
|---|---|---|---|---|---|---|
| Kodiak Sciences KOD | $6.40B | +170% | n/a | -1,361% | 500.31× | 6,084.6% |
| Regeneron Pharmaceuticals REGN | $97.8B | +46% | +19% | 15% | 2.92× | 13.4% |
| Roche RO.SW | $381B | +21% | -1% | 40% | 9.93× | 48.3% |
| Ocular Therapeutix OCUL | $1.31B | -26% | -10% | -93% | 2.96× | 27.2% |
| EyePoint EYPT | n/a | -98% | n/a | n/a | n/a | n/a |
| 4D Molecular Therapeutics FDMT | $578M | +23% | +79,952% | -57% | 1.74× | 32.0% |
| Novartis NOVN.SW | $285B | +11% | -4% | 24% | 7.99× | 32.5% |
| REGENXBIO RGNX | $480M | +22% | -5% | -113% | 3.24× | 29.8% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | KOD | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +5.2% | -6.2% | 8th highest of 21 |
| 6-month return | +170.0% | -1.4% | highest of 21 |
| Return on equity | -1,360.9% | -20.9% | lowest of 21 |
| Price / book | 500.31× | 8.92× | most expensive of 21 |
| ROE the price implies | 6,084.6% | 53.9% | most demanding of 21 |
| ROE delivered | -1,360.9% | -20.9% | lowest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | ROE | Price / book | Implied ROE | Delivered ROE |
|---|---|---|---|---|---|---|---|---|
| Kodiak Sciences KOD | United States | $6.40B | +170% | n/a | -1,361% | 500.31× | 6,084.6% | -1,360.9% |
| Arrowhead Pharmaceuticals ARWR | United States | $6.09B | -44% | -46% | -280% | 121.06× | 1,070.8% | -280.5% |
| Immunovant IMVT | United States | $6.86B | -7% | n/a | -87% | 10.44× | 74.1% | -86.5% |
| Scholar Rock SRRK | United States | $5.86B | -1% | n/a | -200% | 34.70× | 212.2% | -200.0% |
| Axsome Therapeutics AXSM | United States | $7.05B | -42% | +54% | -176% | 66.82× | 426.0% | -175.6% |
| CG Oncology CGON | United States | $7.15B | +24% | +184% | -28% | 7.21× | 30.5% | -28.3% |
| Caris Life Sciences CAI | United States | $5.59B | +24% | +61% | 17% | 8.74× | 51.8% | 17.2% |
| Anthem Biosciences ANTHEM.NS | India | $5.51B | +16% | -1% | 20% | 15.70× | 125.3% | 20.4% |
| 10x Genomics TXG | United States | $7.51B | +138% | -4% | -8% | 8.95× | 112.5% | -8.3% |
| Chongqing Zhifei Biological Products 300122.SZ | China | $5.28B | -1% | -28% | -64% | 2.32× | 24.5% | -63.8% |
| Twist Bioscience TWST | United States | $7.93B | +117% | +22% | -19% | 8.89× | 121.3% | -19.1% |
| Hangzhou Tigermed Consulting 300347.SZ | China | $4.88B | -2% | +16% | -2% | 1.93× | 21.6% | -2.0% |
| Summit Therapeutics SMMT | United States | $8.40B | -41% | n/a | -220% | 14.87× | 56.0% | -220.0% |
| Cogent Biosciences COGT | United States | $4.84B | -16% | n/a | -100% | 10.72× | 44.4% | -99.6% |
| Dianthus Therapeutics DNTH | United States | $4.73B | -5% | -12% | -23% | 3.81× | 39.0% | -22.6% |
| Genscript Biotech 1548.HK | Hong Kong | $8.69B | +133% | +53% | -15% | 2.12× | 14.7% | -15.3% |
| ALTEOGEN 196170.KS | South Korea | $8.80B | -56% | +61% | 46% | 21.49× | 91.7% | 46.3% |
| Adaptive Biotechnologies ADPT | United States | $4.61B | +104% | +18% | -37% | 26.09× | 341.6% | -37.1% |
| Shanghai RAAS Blood Products 002252.SZ | China | $4.57B | -15% | -22% | 3% | 0.94× | 3.8% | 3.3% |
| Edgewise Therapeutics EWTX | United States | $4.53B | +26% | n/a | 92% | 2.77× | 14.2% | 92.1% |
| Changchun High-Tech Industry (Group) 000661.SZ | China | $4.52B | -13% | -18% | -2% | 1.32× | 13.5% | -1.9% |